Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAX-24 vs PCV20 in Adults 65 Years and Older
NCT05297578Phase 2Completed
- Sponsor
- Vaxcyte
- Start
- Jun 2022
- Primary completion
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 24-valent pneumococcal conjugate vaccine in invasive pneumococcal disease (IPD) and Pneumococcal pneumonia (PP) (4 arms), sponsored by Vaxcyte. Primary endpoints: Percentage of Participants Reporting Solicited Local Reactions at 7 days, Percentage of Participants Reporting Solicited Systemic Events at 7 days and 2 more. Started Jun 2022; status: completed.
02
Drugs
24-valent pneumococcal conjugate vaccine
03
Conditions
invasive pneumococcal disease (IPD)Pneumococcal pneumonia (PP)
Beyond the preview
Go deeper on NCT05297578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297578.